Trials in Boston, Massachusetts
Here are the top 10 medical studies for breast cancer in Boston, Massachusetts
Popular Filters
Phase 3 Trials
PI3K Inhibitor
Inavolisib Combination for Breast Cancer
Recruiting0 awardsPhase 2 & 3
Boston, Massachusetts
This trial tests a new drug combination (inavolisib, palbociclib, and fulvestrant) for patients with a specific type of advanced breast cancer that got worse after hormone therapy. The treatment aims to stop cancer cells from growing and spreading by attacking them in different ways.
Monoclonal Antibodies
Trastuzumab Deruxtecan for Breast Cancer
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial is testing a new drug called trastuzumab deruxtecan for patients with advanced breast cancer that hasn't responded to other treatments. The drug works by specifically targeting and killing cancer cells. The study aims to see if this drug helps patients live longer or improves their quality of life compared to other treatments. Trastuzumab deruxtecan has shown significant clinical benefits in treating advanced breast cancer and other similar tumors.
Hormone Therapy
Giredestrant + Palbociclib vs Letrozole + Palbociclib for Breast Cancer
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial will compare two treatments for breast cancer: giredestrant with palbociclib, and letrozole with palbociclib. The trial will measure how well the treatments work and how safe they are.
Trials With No Placebo
Monoclonal Antibodies
BDC-1001 + Nivolumab for Breast Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial tests a new drug, BDC-1001, alone and with another drug, in patients with advanced HER2-positive cancers. BDC-1001 aims to attack cancer cells directly, and the other drug boosts the immune system to fight the cancer.
Chemotherapy Reduction After Surgery for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is studying how well paclitaxel, trastuzumab, and pertuzumab work in eliminating chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery.
PARP Inhibitor
Olaparib + Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.